Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 6;14(1):4.
doi: 10.1186/s13045-020-01017-7.

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Li Xuan  1 , Qifa Liu  2
Affiliations
Review

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Li Xuan et al. J Hematol Oncol. .

Abstract

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.

Keywords: Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Maintenance therapy; Targeted drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;161(2):192–203. doi: 10.1111/bjh.12233. - DOI - PubMed
    1. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878–3885. doi: 10.1182/blood-2015-01-623447. - DOI - PMC - PubMed
    1. Piemontese S, Boumendil A, Labopin M, et al. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. J Hematol Oncol. 2019;12(1):68. doi: 10.1186/s13045-019-0751-4. - DOI - PMC - PubMed
    1. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16(3):872–881. doi: 10.1200/JCO.1998.16.3.872. - DOI - PubMed
    1. Ferrero D, Crisà E, Marmont F, et al. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ann Hematol. 2014;93(8):1391–1400. doi: 10.1007/s00277-014-2047-7. - DOI - PubMed

Publication types

MeSH terms